Connect with us

International

Let’s build something together: Ex-Lowe’s CFO to join Pfizer while Moderna’s David Meline retires; The CEO-partner party rolls on at Flagship

David Denton
→ The two major Covid-19 vaccine competitors, Pfizer and Moderna, will both have new finance chiefs within a week of each other: At Pfizer,…

Published

on

David Denton

→ The two major Covid-19 vaccine competitors, Pfizer and Moderna, will both have new finance chiefs within a week of each other: At Pfizer, David Denton will succeed 15-year vet Frank D’Amelio as CFO on May 2 after three years in charge of finances at home improvement chain Lowe’s. With Pfizer’s M&A wheels always spinning, Denton left as CFO of CVS Health shortly after playing an integral role in the acquisition of Aetna in late 2017.

Meanwhile, David Meline is calling it quits at Moderna, heading back into retirement nearly two years into his tenure as CFO and yielding the stage to Jorge Gomez on May 9. Before taking the CFO job at dental products manufacturer Dentsply Sirona in 2019, Gomez was also finance chief during a 13-year run at Cardinal Health. Meline had retired as Amgen’s CFO until the Moderna position opened up.

Michelle Werner

→ On the heels of Margo Georgiadis’ appointment, Flagship Pioneering has lined up two more CEO-partners, and Michelle Werner kicked things off as the new chief executive of tRNA-focused Alltrna. Since the summer of 2020, Werner was Novartis Oncology’s worldwide franchise head, solid tumors, and her Big Pharma credentials also extend to Bristol Myers Squibb and to AstraZeneca, where she rose to global franchise head in hematology. Shortly after she decamped for Novartis, Calquence won approval in the EU for adult patients with chronic lymphocytic leukemia, a year after the FDA gave it the go-ahead in the same indication.

Michael Severino

Then, the biotech incubator made a splash on Wednesday by enticing AbbVie president and vice chairman Michael Severino into a CEO-partner job for a company to be named later. Before his arrival at AbbVie in 2014, Severino closed out his 10 years at Amgen as SVP, global development and corporate CMO. Our Kyle LaHucik has more on each new CEO-partner.

Nishan de Silva

The white-hot radiopharma space picked up another challenger in October 2021 with Radionetics Oncology, and the Crinetics spinout — backed by 5AM Ventures and Frazier Healthcare Partnershas found a CEO. Nishan de Silva, the president and COO at Poseida from 2015-18, had helmed AFYX Therapeutics and is currently a board member at Selecta Biosciences. He will also sit on the board at Radionetics while leading a team that is projected “to more than double over the coming year,” according to a release.

Paulash Mohsen

Paulash Mohsen is getting his first opportunity as a CEO at Vesigen Therapeutics, a Harvard spinout whose platform tech is dubbed ARMMs (ARRDC1 Mediated Microvesicles). Mohsen spent the last seven years as CBO of Yumanity, a neuro biotech that’s hanging on for dear life after laying off 60% of the workforce. Yumanity’s pipeline fortunes have soured because of a partial clinical hold on its lead Parkinson’s candidate, and while the company explores its options to stay afloat, Mohsen has jumped ship to a company that launched in July 2020 with help from Leaps by Bayer and Morningside Ventures.

Mario David Saltarelli is stepping into atai Life Sciences platform company GABA Therapeutics as CEO and CMO, succeeding co-founder Ian Massey. Saltarelli takes over the helm — as the company is entering Phase II studies in anxiety, depression and other neurological indications for its lead compound — with a wealth of experience from exec roles at Neuron23 (CEO), Entrada Therapeutics (CMO), Sytimmune (CMO), Annexon Biosciences (CMO) and Mallinckrodt (CSO). This is all on top of other stints at Pfizer, Shire, Vertex, Alexion and Abbott.

Ranna Parekh

→ The University of Texas MD Anderson Cancer Center will welcome Ranna Parekh as chief diversity, equity and inclusion officer on May 31. Parekh comes from the American College of Cardiology in Washington, where she was the organiza1tion’s first chief diversity and inclusion officer, and she’s also held DEI leadership posts at the American Psychiatric Association.

Joerg Hornstein

Joerg Hornstein has bolted from AC Immune to become CFO and head of corporate functions for Lundbeck, which provided a foretaste of the industry-wide staff cuts we’re seeing today by slashing 300 jobs and shuttering its facility in India. Hornstein had handled finances at AC Immune since 2017 and also spent 12 years in multiple locations at Merck KGaA.

As for Hornstein’s replacement at the Swiss neuro biotech, Chris Roberts will pinch-hit as interim CFO and has been promoted to VP, finance. Roberts joined Andrea Pfeifer’s crew as an associate VP in 2017 after more than a decade at Ernst & Young.

AC Immune also made two other leadership moves with Howard Donovan as chief HR officer and the promotion of Julian Snow to VP, US finance & corporate development. Donovan pivots here from the World Economic Forum, where he was head of people and culture partners, people services and global reward. As with Roberts, Snow started at AC Immune five years ago, filling the role of associate VP, financial reporting.

Gina Consylman

Gina Consylman has landed at Cyrus Mozayeni-led Vedere Bio II from bluebird bio as CFO. Consylman starts anew quickly at the ocular gene therapy player, which debuted in May 2021 with a $77 million Series A, after a dire quarterly filing coincided with her departure from bluebird bio. Consylman joined bluebird just eight months ago after seven years as CFO of Ironwood, which has had its own set of obstacles with its pipeline and saw CEO Mark Mallon leave for NeoGenomics last year.

John Frank

→ DNA sequencing powerhouse Illumina has poached John Frank from Microsoft, naming him chief public affairs officer. Frank, whose first day will be April 18, wraps up a 28-year career with the tech giant, starting out as a senior attorney and ascending to deputy general counsel & chief of staff. Since March 2020, Frank has taken on the role of VP, United Nations affairs and international organizations.

Sam Jackson

→ Sitting pretty with a $100 million financing round just a couple weeks ago and targeting LRRK2 and TYK2, CNS-focused Neuron23 has tapped Sam Jackson as CMO. Jackson hails from another neuro player, Alector, where he held the same position and where former Passage Bio exec Gary Romano will soon replace him. Jackson is a Genentech and Amgen vet who was also the CMO of Alkahest.

Raffaele Baffa

Raffaele Baffa has signed on to be CMO at CARsgen, which is attempting to wedge its way into the BCMA CAR-T space with CT053 for multiple myeloma. Baffa pivots to CARSgen from Ziopharm Oncology (now known as Alaunos after the activist attack dust has settled), where he was CMO and EVP of R&D. The Sanofi and Pfizer vet has also been CMO of Servier and VP, therapeutic area head of oncology, global clinical development at Shire.

Jan Pinkas has been elevated to CSO of Pyxis Oncology as Ronald Herbst parts ways with the Pfizer ADC spinout. Last August, Pinkas joined Pyxis — which hit Nasdaq the following October on the strength of a $168 million IPO — as SVP, preclinical R&D after a two-year stint at Magenta Therapeutics as SVP, translational sciences. He also had a number of responsibilities over a 12-year period at ImmunoGen, namely VP, translational R&D.

Ravi Rao

Eli Lilly immunometabolism partner Sitryx Therapeutics out of Oxford has selected Ravi Rao as CMO. Rao — a former GlaxoSmithKline exec in immunology and specialty medicines who was also a group medical director, immunology clinical development with Roche — was head of R&D and CMO at Sobi before choosing a different path here at GSK-backed Sitryx. Anders Ullman has since taken over Rao’s old posts at Sobi.

Mikael Eliasson

→ Helmed by Stanford’s Amit Etkin, psychiatry startup Alto Neuroscience has looked toward Genentech/Roche to appoint Mikael Eliasson as COO. Eliasson, who was previously Genentech/Roche’s global head of innovation in neuroscience product development, has also been global head of new products at Novartis. Christian Angermayer and the folks at Apeiron Investment Group led Alto Neuroscience’s Series A round last October, bringing the total raised to $40 million.

Jotin Marango has left Aptose to tackle the dual roles of CFO and head of corporate development with Ikena Oncology, which is partnering with Bristol Myers on its oral AHR inhibitor IK-175. Marango had been CFO and CBO at Aptose, prompting a leadership shuffle in which CEO William Rice is picking up the slack as chief accounting officer and VP of finance Janet Clennett “will assume financial responsibilities until a permanent CFO is announced.”

Karen Davies

→ Co-founded by Feng Zhang and padding its war chest with an $80 million Series B last month, CRISPR diagnostic player Sherlock Biosciences has trained a magnifying glass on Karen Davies as chief development officer. For the past decade, Davies has held a series of posts at fellow diagnostic developer Quidel — from 2017-20 she was VP of instrument systems, and since 2020 she served as VP of business transformation.

Amanda Murphy

Amanda Murphy has resigned from her role as CFO at cell engineering player MaxCyte, effective April 15. Ron Holtz, the current SVP and chief accounting officer, will take over as interim CFO. While Korn Ferry helps in the search for a successor, Holtz is returning to the role he first held at MaxCyte from 2005-20. Elsewhere, MaxCyte staffer Sean Menarguez has been bumped up to director, investor relations.

Shabir Hasham

→ Seeking to put a bow on an NDA filing for its Duchenne muscular dystrophy drug vamorolone by June, Santhera has promoted Shabir Hasham to CMO. Hasham left Novartis in 2015 to become Santhera’s head of medical affairs EU & RoW, and since 2019 he’s been global development program lead & global head medical affairs. While with Novartis, Hasham was EU medical director and global associate brand director for the Swiss pharma’s neuroscience franchise. Hasham’s first day as medical chief is slated for May 1.

Cristina Oliva

Cristina Oliva is making her way over to Norway-based BerGenBio, where she’ll serve as CMO. Oliva hops aboard after a stint as VP, oncology and head of oncology centre of excellence at IQVIA. Oliva’s résumé includes a star-studded career with previous roles at Nordic Nanovector, Takeda, GSK and Eli Lilly.

→ Undergoing a facelift by officially renaming itself a couple weeks ago, Swedish cancer outfit Vivesto — once known as Oasmiahas pegged Daniel Tesfa as CMO. Tesfa had been medical director, clinical and translation science hematology at Sobi since leading oncology and hematology for Bayer in Scandinavia from 2018-20. Vivesto will utilize Lonza’s expanded site in Nansha, China, striking a deal in late March with the CDMO to manufacture late-stage ovarian cancer candidate Cantrixil.

Alliance Pharma is locking in Patrick Bennett to helm the bioanalytical services company as CEO, succeeding founder Frank Li, who will remain as president and on the board of directors. Bennett brings with him experience from his time at PPD Laboratories (VP, strategy and development) and Thermo Fisher Scientific (director of global strategic marketing).

Richard Bartram

→ Peptide specialist MBX Biosciences is picking up former Esperion exec Richard Bartram as CFO. Bartram served in the same role during his time at Esperion — helping to raise more than $1.2 billion in capital. Prior to that stint, Bartram was with PricewaterhouseCoopers.

Vaxxas, the company that Merck teamed up with back in 2020 to tap into patch delivery tech, has named Dan Devine as CBO and general counsel. Devine joins the Brisbane, Australia-based company with experience from his roles at Pfizer, Patrys and Mesoblast.

James Gruber

James Gruber has been named CFO at Alkindi Sprinkle maker Eton Pharmaceuticals, taking over the position from Wilson Troutman, who will retire at the end of May. Gruber most recently served as US controller at Horizon Therapeutics and he also spent more than a decade working in various financial positions at Abbott.

Libbie Mansell

→ As the calendar flipped to 2022, Javier Szwarcberg was named CEO of Spruce Biosciences, and now the Mike Grey-chaired biotech focused on rare endocrine disorders has brought in Libbie Mansell as chief regulatory and quality officer. If it seems like it wasn’t that long ago since Mansell appeared in Peer Review, you’re right: Six months ago she joined NFLection Therapeutics as SVP of global regulatory affairs & quality assurance, but it’s on to the next challenge. Mansell was also part of the AskBio team as SVP of regulatory affairs.

Nautilus Biotechnology — backed by Paul Allen and Jeff Bezos and setting sail for Nasdaq via one of Perceptive’s blank-check companies last year — has signed on Gwen Weld as chief people officer and Sheri Wilcox as VP of affinity reagent development. Prior to joining Nautilus, Weld was chief people officer at Amperity and formerly general manager of human resources at Microsoft. Meanwhile, Wilcox hails from SomaLogic. where she served as senior director of global scientific engagement. Before that, she was with Pharmacia.

Karina Fedasz, who began her career at JP Morgan and was recently the CFO of IDW Media Holdings, has been named head of business development at Evofem, the maker of contraceptive gel Phexxi. In February, Endpoints News’ Beth Snyder Bulik spoke with Evofem CEO Saundra Pelletier about a number of topics, namely Phexxi’s ad campaign featuring “Schitt’s Creek” star Annie Murphy.

Heather Vital

Jo Viney’s Seismic Therapeutic, using machine learning to develop immunology drugs and launching with a tectonic plate-shifting $101 million Series A in February, has added two execs: Eric Larson (SVP of finance) reunites with Viney, the CEO of Pandion before it was sold to Merck for $1.85 billion last year. Before Larson was Viney’s VP of finance, he served as corporate controller for Proteostasis Therapeutics. After nearly seven years with Biogen, Heather Vital (VP of R&D strategy) jumped to Deciphera Pharmaceuticals as senior director of program leadership and then moved on to her most recent gig as senior director, portfolio strategy and operations for Relay Therapeutics.

→ TCR biotech TScan Therapeutics has a new VP, finance in Leiden Dworak, who was previously VP, head of financial planning and analysis and business operations at Avrobio. Dworak has also served as the finance lead for global vaccines business development at Moderna.

Lyndah Dreiling

→ California-based Korlym maker Corcept Therapeutics has three new execs ready to roll: First, Daniel Einhorn (VP, endocrine strategy) was the president of Diabetes and Endocrine Associates and medical director of Scripps Whittier Diabetes Institute in San Diego. Amiel Balagtas (VP, development operations) joins the list of Gilead vets at Corcept that includes chief HR and communications officer Amy Flood and chief development officer William Guyer, capping off a 23-year career at the Big Pharma as executive director, development systems. And Lyndah Dreiling (VP, global oncology development), who also has Gilead ties as senior director, clinical research oncology, is an Amgen alum who was recently SVP, clinical development with Spectrum Pharmaceuticals.

→ New Jersey-based Cellectar Biosciences has two announcements this week: Matthew Hagan has been appointed VP, marketing and strategic alliances, and David Lasecki has joined the oncology biotech as executive director, strategic alliances. Most recently, Hagan served as executive director, hematology portfolio marketing at Bristol Myers. Lasecki joins from Heron Therapeutics, where he served as senior director, oncology sales.

Michael Morrissey

Exelixis president and CEO Michael Morrissey has been named chairman of the board at Vera Therapeutics, stepping into the spot previously occupied by Abingworth’s Kurt von Emster. The atacicept developer’s board also includes Beth Seidenberg from Westlake Village BioPartners and Akero Therapeutics CEO Andrew Cheng.

→ There’s a changing of the guard on the board of directors at Cytokinetics, as John Henderson replaces the retiring Robert Gage. Henderson, a 25-year Pfizer vet, has been on the board at Cytokinetics since 2009. Cardiologist and Stanford Department of Medicine chairman Robert Harrington has also earned a seat on Cytokinetics’ board.

Maria Fardis

CRISPR Therapeutics has put Maria Fardis’ name forward to join the board of directors. When her time was up as CEO of Iovance, Fardis then became a venture partner at Frazier Life Sciences. If elected, Fardis would take a seat at a board that includes SR One’s Simeon George and AskBio’s Kathy High.

Michel Detheux, the president and CEO of iTeos Therapeutics, has assumed the role of chairman of the board at French rare bone disease biotech InnoSkel. Detheux co-founded iTeos 10 years ago and is also chairman of ONA Therapeutics in Barcelona.

Lipocine has brought on Jill Jene and Spyros Papapetropoulos to its board of directors. Jene is currently founder and principal of Jene Advisors and has previously served as VP and head of corporate development, strategy, portfolio planning and alliance management at Adamas. Meanwhile, Papapetropoulos is the CMO of Vigil Neurosciences and was formerly SVP, head of development at Acadia Pharmaceuticals, CEO of SwanBio Therapeutics and head of research & development and CMO at Cavion.

Read More

Continue Reading

International

Copper Soars, Iron Ore Tumbles As Goldman Says “Copper’s Time Is Now”

Copper Soars, Iron Ore Tumbles As Goldman Says "Copper’s Time Is Now"

After languishing for the past two years in a tight range despite recurring…

Published

on

Copper Soars, Iron Ore Tumbles As Goldman Says "Copper's Time Is Now"

After languishing for the past two years in a tight range despite recurring speculation about declining global supply, copper has finally broken out, surging to the highest price in the past year, just shy of $9,000 a ton as supply cuts hit the market; At the same time the price of the world's "other" most important mined commodity has diverged, as iron ore has tumbled amid growing demand headwinds out of China's comatose housing sector where not even ghost cities are being built any more.

Copper surged almost 5% this week, ending a months-long spell of inertia, as investors focused on risks to supply at various global mines and smelters. As Bloomberg adds, traders also warmed to the idea that the worst of a global downturn is in the past, particularly for metals like copper that are increasingly used in electric vehicles and renewables.

Yet the commodity crash of recent years is hardly over, as signs of the headwinds in traditional industrial sectors are still all too obvious in the iron ore market, where futures fell below $100 a ton for the first time in seven months on Friday as investors bet that China’s years-long property crisis will run through 2024, keeping a lid on demand.

Indeed, while the mood surrounding copper has turned almost euphoric, sentiment on iron ore has soured since the conclusion of the latest National People’s Congress in Beijing, where the CCP set a 5% goal for economic growth, but offered few new measures that would boost infrastructure or other construction-intensive sectors.

As a result, the main steelmaking ingredient has shed more than 30% since early January as hopes of a meaningful revival in construction activity faded. Loss-making steel mills are buying less ore, and stockpiles are piling up at Chinese ports. The latest drop will embolden those who believe that the effects of President Xi Jinping’s property crackdown still have significant room to run, and that last year’s rally in iron ore may have been a false dawn.

Meanwhile, as Bloomberg notes, on Friday there were fresh signs that weakness in China’s industrial economy is hitting the copper market too, with stockpiles tracked by the Shanghai Futures Exchange surging to the highest level since the early days of the pandemic. The hope is that headwinds in traditional industrial areas will be offset by an ongoing surge in usage in electric vehicles and renewables.

And while industrial conditions in Europe and the US also look soft, there’s growing optimism about copper usage in India, where rising investment has helped fuel blowout growth rates of more than 8% — making it the fastest-growing major economy.

In any case, with the demand side of the equation still questionable, the main catalyst behind copper’s powerful rally is an unexpected tightening in global mine supplies, driven mainly by last year’s closure of a giant mine in Panama (discussed here), but there are also growing worries about output in Zambia, which is facing an El Niño-induced power crisis.

On Wednesday, copper prices jumped on huge volumes after smelters in China held a crisis meeting on how to cope with a sharp drop in processing fees following disruptions to supplies of mined ore. The group stopped short of coordinated production cuts, but pledged to re-arrange maintenance work, reduce runs and delay the startup of new projects. In the coming weeks investors will be watching Shanghai exchange inventories closely to gauge both the strength of demand and the extent of any capacity curtailments.

“The increase in SHFE stockpiles has been bigger than we’d anticipated, but we expect to see them coming down over the next few weeks,” Colin Hamilton, managing director for commodities research at BMO Capital Markets, said by phone. “If the pace of the inventory builds doesn’t start to slow, investors will start to question whether smelters are actually cutting and whether the impact of weak construction activity is starting to weigh more heavily on the market.”

* * *

Few have been as happy with the recent surge in copper prices as Goldman's commodity team, where copper has long been a preferred trade (even if it may have cost the former team head Jeff Currie his job due to his unbridled enthusiasm for copper in the past two years which saw many hedge fund clients suffer major losses).

As Goldman's Nicholas Snowdon writes in a note titled "Copper's time is now" (available to pro subscribers in the usual place)...

... there has been a "turn in the industrial cycle." Specifically according to the Goldman analyst, after a prolonged downturn, "incremental evidence now points to a bottoming out in the industrial cycle, with the global manufacturing PMI in expansion for the first time since September 2022." As a result, Goldman now expects copper to rise to $10,000/t by year-end and then $12,000/t by end of Q1-25.’

Here are the details:

Previous inflexions in global manufacturing cycles have been associated with subsequent sustained industrial metals upside, with copper and aluminium rising on average 25% and 9% over the next 12 months. Whilst seasonal surpluses have so far limited a tightening alignment at a micro level, we expect deficit inflexions to play out from quarter end, particularly for metals with severe supply binds. Supplemented by the influence of anticipated Fed easing ahead in a non-recessionary growth setting, another historically positive performance factor for metals, this should support further upside ahead with copper the headline act in this regard.

Goldman then turns to what it calls China's "green policy put":

Much of the recent focus on the “Two Sessions” event centred on the lack of significant broad stimulus, and in particular the limited property support. In our view it would be wrong – just as in 2022 and 2023 – to assume that this will result in weak onshore metals demand. Beijing’s emphasis on rapid growth in the metals intensive green economy, as an offset to property declines, continues to act as a policy put for green metals demand. After last year’s strong trends, evidence year-to-date is again supportive with aluminium and copper apparent demand rising 17% and 12% y/y respectively. Moreover, the potential for a ‘cash for clunkers’ initiative could provide meaningful right tail risk to that healthy demand base case. Yet there are also clear metal losers in this divergent policy setting, with ongoing pressure on property related steel demand generating recent sharp iron ore downside.

Meanwhile, Snowdon believes that the driver behind Goldman's long-running bullish view on copper - a global supply shock - continues:

Copper’s supply shock progresses. The metal with most significant upside potential is copper, in our view. The supply shock which began with aggressive concentrate destocking and then sharp mine supply downgrades last year, has now advanced to an increasing bind on metal production, as reflected in this week's China smelter supply rationing signal. With continued positive momentum in China's copper demand, a healthy refined import trend should generate a substantial ex-China refined deficit this year. With LME stocks having halved from Q4 peak, China’s imminent seasonal demand inflection should accelerate a path into extreme tightness by H2. Structural supply underinvestment, best reflected in peak mine supply we expect next year, implies that demand destruction will need to be the persistent solver on scarcity, an effect requiring substantially higher pricing than current, in our view. In this context, we maintain our view that the copper price will surge into next year (GSe 2025 $15,000/t average), expecting copper to rise to $10,000/t by year-end and then $12,000/t by end of Q1-25’

Another reason why Goldman is doubling down on its bullish copper outlook: gold.

The sharp rally in gold price since the beginning of March has ended the period of consolidation that had been present since late December. Whilst the initial catalyst for the break higher came from a (gold) supportive turn in US data and real rates, the move has been significantly amplified by short term systematic buying, which suggests less sticky upside. In this context, we expect gold to consolidate for now, with our economists near term view on rates and the dollar suggesting limited near-term catalysts for further upside momentum. Yet, a substantive retracement lower will also likely be limited by resilience in physical buying channels. Nonetheless, in the midterm we continue to hold a constructive view on gold underpinned by persistent strength in EM demand as well as eventual Fed easing, which should crucially reactivate the largely for now dormant ETF buying channel. In this context, we increase our average gold price forecast for 2024 from $2,090/toz to $2,180/toz, targeting a move to $2,300/toz by year-end.

Much more in the full Goldman note available to pro subs.

Tyler Durden Fri, 03/15/2024 - 14:25

Read More

Continue Reading

International

The millions of people not looking for work in the UK may be prioritising education, health and freedom

Economic inactivity is not always the worst option.

Published

on

By

Taking time out. pathdoc/Shutterstock

Around one in five British people of working age (16-64) are now outside the labour market. Neither in work nor looking for work, they are officially labelled as “economically inactive”.

Some of those 9.2 million people are in education, with many students not active in the labour market because they are studying full-time. Others are older workers who have chosen to take early retirement.

But that still leaves a large number who are not part of the labour market because they are unable to work. And one key driver of economic inactivity in recent years has been illness.

This increase in economic inactivity – which has grown since before the pandemic – is not just harming the economy, but also indicative of a deeper health crisis.

For those suffering ill health, there are real constraints on access to work. People with health-limiting conditions cannot just slot into jobs that are available. They need help to address the illnesses they have, and to re-engage with work through organisations offering supportive and healthy work environments.

And for other groups, such as stay-at-home parents, businesses need to offer flexible work arrangements and subsidised childcare to support the transition from economic inactivity into work.

The government has a role to play too. Most obviously, it could increase investment in the NHS. Rising levels of poor health are linked to years of under-investment in the health sector and economic inactivity will not be tackled without more funding.

Carrots and sticks

For the time being though, the UK government appears to prefer an approach which mixes carrots and sticks. In the March 2024 budget, for example, the chancellor cut national insurance by 2p as a way of “making work pay”.

But it is unclear whether small tax changes like this will have any effect on attracting the economically inactive back into work.

Jeremy Hunt also extended free childcare. But again, questions remain over whether this is sufficient to remove barriers to work for those with parental responsibilities. The high cost and lack of availability of childcare remain key weaknesses in the UK economy.

The benefit system meanwhile has been designed to push people into work. Benefits in the UK remain relatively ungenerous and hard to access compared with other rich countries. But labour shortages won’t be solved by simply forcing the economically inactive into work, because not all of them are ready or able to comply.

It is also worth noting that work itself may be a cause of bad health. The notion of “bad work” – work that does not pay enough and is unrewarding in other ways – can lead to economic inactivity.

There is also evidence that as work has become more intensive over recent decades, for some people, work itself has become a health risk.

The pandemic showed us how certain groups of workers (including so-called “essential workers”) suffered more ill health due to their greater exposure to COVID. But there are broader trends towards lower quality work that predate the pandemic, and these trends suggest improving job quality is an important step towards tackling the underlying causes of economic inactivity.

Freedom

Another big section of the economically active population who cannot be ignored are those who have retired early and deliberately left the labour market behind. These are people who want and value – and crucially, can afford – a life without work.

Here, the effects of the pandemic can be seen again. During those years of lockdowns, furlough and remote working, many of us reassessed our relationship with our jobs. Changed attitudes towards work among some (mostly older) workers can explain why they are no longer in the labour market and why they may be unresponsive to job offers of any kind.

Sign on railings supporting NHS staff during pandemic.
COVID made many people reassess their priorities. Alex Yeung/Shutterstock

And maybe it is from this viewpoint that we should ultimately be looking at economic inactivity – that it is actually a sign of progress. That it represents a move towards freedom from the drudgery of work and the ability of some people to live as they wish.

There are utopian visions of the future, for example, which suggest that individual and collective freedom could be dramatically increased by paying people a universal basic income.

In the meantime, for plenty of working age people, economic inactivity is a direct result of ill health and sickness. So it may be that the levels of economic inactivity right now merely show how far we are from being a society which actually supports its citizens’ wellbeing.

David Spencer has received funding from the ESRC.

Read More

Continue Reading

International

Illegal Immigrants Leave US Hospitals With Billions In Unpaid Bills

Illegal Immigrants Leave US Hospitals With Billions In Unpaid Bills

By Autumn Spredemann of The Epoch Times

Tens of thousands of illegal…

Published

on

Illegal Immigrants Leave US Hospitals With Billions In Unpaid Bills

By Autumn Spredemann of The Epoch Times

Tens of thousands of illegal immigrants are flooding into U.S. hospitals for treatment and leaving billions in uncompensated health care costs in their wake.

The House Committee on Homeland Security recently released a report illustrating that from the estimated $451 billion in annual costs stemming from the U.S. border crisis, a significant portion is going to health care for illegal immigrants.

With the majority of the illegal immigrant population lacking any kind of medical insurance, hospitals and government welfare programs such as Medicaid are feeling the weight of these unanticipated costs.

Apprehensions of illegal immigrants at the U.S. border have jumped 48 percent since the record in fiscal year 2021 and nearly tripled since fiscal year 2019, according to Customs and Border Protection data.

Last year broke a new record high for illegal border crossings, surpassing more than 3.2 million apprehensions.

And with that sea of humanity comes the need for health care and, in most cases, the inability to pay for it.

In January, CEO of Denver Health Donna Lynne told reporters that 8,000 illegal immigrants made roughly 20,000 visits to the city’s health system in 2023.

The total bill for uncompensated care costs last year to the system totaled $140 million, said Dane Roper, public information officer for Denver Health. More than $10 million of it was attributed to “care for new immigrants,” he told The Epoch Times.

Though the amount of debt assigned to illegal immigrants is a fraction of the total, uncompensated care costs in the Denver Health system have risen dramatically over the past few years.

The total uncompensated costs in 2020 came to $60 million, Mr. Roper said. In 2022, the number doubled, hitting $120 million.

He also said their city hospitals are treating issues such as “respiratory illnesses, GI [gastro-intenstinal] illnesses, dental disease, and some common chronic illnesses such as asthma and diabetes.”

“The perspective we’ve been trying to emphasize all along is that providing healthcare services for an influx of new immigrants who are unable to pay for their care is adding additional strain to an already significant uncompensated care burden,” Mr. Roper said.

He added this is why a local, state, and federal response to the needs of the new illegal immigrant population is “so important.”

Colorado is far from the only state struggling with a trail of unpaid hospital bills.

EMS medics with the Houston Fire Department transport a Mexican woman the hospital in Houston on Aug. 12, 2020. (John Moore/Getty Images)

Dr. Robert Trenschel, CEO of the Yuma Regional Medical Center situated on the Arizona–Mexico border, said on average, illegal immigrants cost up to three times more in human resources to resolve their cases and provide a safe discharge.

“Some [illegal] migrants come with minor ailments, but many of them come in with significant disease,” Dr. Trenschel said during a congressional hearing last year.

“We’ve had migrant patients on dialysis, cardiac catheterization, and in need of heart surgery. Many are very sick.”

He said many illegal immigrants who enter the country and need medical assistance end up staying in the ICU ward for 60 days or more.

A large portion of the patients are pregnant women who’ve had little to no prenatal treatment. This has resulted in an increase in babies being born that require neonatal care for 30 days or longer.

Dr. Trenschel told The Epoch Times last year that illegal immigrants were overrunning healthcare services in his town, leaving the hospital with $26 million in unpaid medical bills in just 12 months.

ER Duty to Care

The Emergency Medical Treatment and Labor Act of 1986 requires that public hospitals participating in Medicare “must medically screen all persons seeking emergency care … regardless of payment method or insurance status.”

The numbers are difficult to gauge as the policy position of the Centers for Medicare & Medicaid Services (CMS) is that it “will not require hospital staff to ask patients directly about their citizenship or immigration status.”

In southern California, again close to the border with Mexico, some hospitals are struggling with an influx of illegal immigrants.

American patients are enduring longer wait times for doctor appointments due to a nursing shortage in the state, two health care professionals told The Epoch Times in January.

A health care worker at a hospital in Southern California, who asked not to be named for fear of losing her job, told The Epoch Times that “the entire health care system is just being bombarded” by a steady stream of illegal immigrants.

“Our healthcare system is so overwhelmed, and then add on top of that tuberculosis, COVID-19, and other diseases from all over the world,” she said.

A Salvadorian man is aided by medical workers after cutting his leg while trying to jump on a truck in Matias Romero, Mexico, on Nov. 2, 2018. (Spencer Platt/Getty Images)

A newly-enacted law in California provides free healthcare for all illegal immigrants residing in the state. The law could cost taxpayers between $3 billion and $6 billion per year, according to recent estimates by state and federal lawmakers.

In New York, where the illegal immigration crisis has manifested most notably beyond the southern border, city and state officials have long been accommodating of illegal immigrants’ healthcare costs.

Since June 2014, when then-mayor Bill de Blasio set up The Task Force on Immigrant Health Care Access, New York City has worked to expand avenues for illegal immigrants to get free health care.

“New York City has a moral duty to ensure that all its residents have meaningful access to needed health care, regardless of their immigration status or ability to pay,” Mr. de Blasio stated in a 2015 report.

The report notes that in 2013, nearly 64 percent of illegal immigrants were uninsured. Since then, tens of thousands of illegal immigrants have settled in the city.

“The uninsured rate for undocumented immigrants is more than three times that of other noncitizens in New York City (20 percent) and more than six times greater than the uninsured rate for the rest of the city (10 percent),” the report states.

The report states that because healthcare providers don’t ask patients about documentation status, the task force lacks “data specific to undocumented patients.”

Some health care providers say a big part of the issue is that without a clear path to insurance or payment for non-emergency services, illegal immigrants are going to the hospital due to a lack of options.

“It’s insane, and it has been for years at this point,” Dana, a Texas emergency room nurse who asked to have her full name omitted, told The Epoch Times.

Working for a major hospital system in the greater Houston area, Dana has seen “a zillion” migrants pass through under her watch with “no end in sight.” She said many who are illegal immigrants arrive with treatable illnesses that require simple antibiotics. “Not a lot of GPs [general practitioners] will see you if you can’t pay and don’t have insurance.”

She said the “undocumented crowd” tends to arrive with a lot of the same conditions. Many find their way to Houston not long after crossing the southern border. Some of the common health issues Dana encounters include dehydration, unhealed fractures, respiratory illnesses, stomach ailments, and pregnancy-related concerns.

“This isn’t a new problem, it’s just worse now,” Dana said.

Emergency room nurses and EMTs tend to patients in hallways at the Houston Methodist The Woodlands Hospital in Houston on Aug. 18, 2021. (Brandon Bell/Getty Images)

Medicaid Factor

One of the main government healthcare resources illegal immigrants use is Medicaid.

All those who don’t qualify for regular Medicaid are eligible for Emergency Medicaid, regardless of immigration status. By doing this, the program helps pay for the cost of uncompensated care bills at qualifying hospitals.

However, some loopholes allow access to the regular Medicaid benefits. “Qualified noncitizens” who haven’t been granted legal status within five years still qualify if they’re listed as a refugee, an asylum seeker, or a Cuban or Haitian national.

Yet the lion’s share of Medicaid usage by illegal immigrants still comes through state-level benefits and emergency medical treatment.

A Congressional report highlighted data from the CMS, which showed total Medicaid costs for “emergency services for undocumented aliens” in fiscal year 2021 surpassed $7 billion, and totaled more than $5 billion in fiscal 2022.

Both years represent a significant spike from the $3 billion in fiscal 2020.

An employee working with Medicaid who asked to be referred to only as Jennifer out of concern for her job, told The Epoch Times that at a state level, it’s easy for an illegal immigrant to access the program benefits.

Jennifer said that when exceptions are sent from states to CMS for approval, “denial is actually super rare. It’s usually always approved.”

She also said it comes as no surprise that many of the states with the highest amount of Medicaid spending are sanctuary states, which tend to have policies and laws that shield illegal immigrants from federal immigration authorities.

Moreover, Jennifer said there are ways for states to get around CMS guidelines. “It’s not easy, but it can and has been done.”

The first generation of illegal immigrants who arrive to the United States tend to be healthy enough to pass any pre-screenings, but Jennifer has observed that the subsequent generations tend to be sicker and require more access to care. If a family is illegally present, they tend to use Emergency Medicaid or nothing at all.

The Epoch Times asked Medicaid Services to provide the most recent data for the total uncompensated care that hospitals have reported. The agency didn’t respond.

Continue reading over at The Epoch Times

Tyler Durden Fri, 03/15/2024 - 09:45

Read More

Continue Reading

Trending